Compare ANTX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANTX | KRRO |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.6M | 150.0M |
| IPO Year | 2022 | 2019 |
| Metric | ANTX | KRRO |
|---|---|---|
| Price | $4.75 | $12.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $2.00 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 334.8K | 144.5K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $1.00 | $5.20 |
| 52 Week High | $6.91 | $55.89 |
| Indicator | ANTX | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 70.62 | 47.56 |
| Support Level | $1.06 | $12.51 |
| Resistance Level | $6.91 | $14.76 |
| Average True Range (ATR) | 0.36 | 0.77 |
| MACD | 0.13 | -0.19 |
| Stochastic Oscillator | 81.23 | 10.05 |
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.